The company's success hinges on the successful commercialization of its next-generation products and resolving its manufacturing challenges. Traders should monitor the launch of the MiniMed Flex pump and the Vivera algorithm, as well as the company's ability to improve margins and achieve profitability.
Executive Summary
MiniMed Group, Inc. is a global medical technology company spun off from Medtronic, focused on diabetes management through its integrated Automated Insulin Delivery (AID) systems, including the flagship MiniMed 780G. The company is commercializing a full-stack solution with insulin pumps, CGMs, and proprietary dosing algorithms, achieving strong clinical outcomes and market leadership with over 640,000 pump users. It is raising $712 million in an IPO to fund its separation, with strong double-digit revenue growth but recent net losses due to R&D and manufacturing challenges.
Key Financial Metrics
Key Facts
- MiniMed is the only company to commercialize a fully integrated AID system with its own pumps, CGMs, and dosing algorithms, giving it a significant competitive advantage.
- The company generated $2.7 billion in revenue in FY25, with 80% from consumables, software, and services, indicating a durable revenue base.
- It achieved $253 million in Adjusted EBITDA in FY25 but reported a $198 million net loss, reflecting heavy investment in R&D and a $118 million charge for terminating a manufacturing agreement.
- The company is launching a new product pipeline, including the MiniMed Flex pump and Vivera dosing algorithm, while expanding into the insulin-requiring Type 2 diabetes market.
- Post-IPO, Medtronic will retain 90% of voting power, making the company a controlled entity, and the IPO proceeds will be used to repay intercompany debt and retain $350 million in cash.
Financial Impact
The company has a strong growth trajectory with double-digit revenue growth but is currently unprofitable. The IPO will provide $712 million in net proceeds to fund operations and separation costs.
Risk Factors
- The company is currently unprofitable and has significant net losses.
- It faces substantial risks from its reliance on a single supplier for infusion sets, which received a U.S. FDA warning letter.
- The company's manufacturing of Simplera CGMs has faced delays and a $118 million charge for terminating a manufacturing agreement.
- Post-IPO, Medtronic will retain 90% of voting power, which could limit the influence of public shareholders.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001628280-26-012865 |
| Exhibit: exhibit231-sx1a3.htm | 0001628280-26-012865 |
| Document: 0001628280-26-012865-index-headers.html | 0001628280-26-012865 |
| Document: 0001628280-26-012865-index.html | 0001628280-26-012865 |
| Document: 0001628280-26-012865.txt | 0001628280-26-012865 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | โผ โ3.87% | โผ โ3.98% | $19.56 (โ10.97%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | โผ โ3.87% | โผ โ3.98% | $19.56 (โ10.97%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | โผ โ3.87% | โผ โ3.98% | $19.56 (โ10.97%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | โผ โ3.87% | โผ โ3.98% | $19.56 (โ10.97%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | โผ โ3.87% | โผ โ3.98% | $19.56 (โ10.97%) |
Sep 14, 2026 18d ago | 425 | $21.97 $21.12 | โผ โ3.87% | โผ โ3.98% | $19.56 (โ10.97%) |
Sep 14, 2026 18d ago | S-4 / 425 | $21.97 $21.12 | โผ โ3.87% | โผ โ3.98% | $19.56 (โ10.97%) |
Sep 1, 2026 4w ago | 8-K | $22.42 $22.76 | โฒ +1.52% | โฒ +1.44% | $19.56 (โ12.76%) |
Jul 6, 2026 12w ago | 3 | $15.37 $15.04 | โผ โ2.15% | โผ โ2.70% | $19.56 (+27.26%) |
Jun 29, 2026 13w ago | 8-K | $14.88 $15.29 | โฒ +2.76% | โฒ +1.37% | $19.56 (+31.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access